Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Local complement activation is associated with primary graft dysfunction after lung transplantation
Hrishikesh S. Kulkarni, … , Andrew E. Gelman, Joshua M. Diamond
Hrishikesh S. Kulkarni, … , Andrew E. Gelman, Joshua M. Diamond
Published August 4, 2020
Citation Information: JCI Insight. 2020;5(17):e138358. https://doi.org/10.1172/jci.insight.138358.
View: Text | PDF
Clinical Research and Public Health Pulmonology

Local complement activation is associated with primary graft dysfunction after lung transplantation

  • Text
  • PDF
Abstract

BACKGROUND The complement system plays a key role in host defense but is activated by ischemia/reperfusion injury (IRI). Primary graft dysfunction (PGD) is a form of acute lung injury occurring predominantly due to IRI, which worsens survival after lung transplantation (LTx). Local complement activation is associated with acute lung injury, but whether it is more reflective of allograft injury compared with systemic activation remains unclear. We proposed that local complement activation would help identify those who develop PGD after LTx. We also aimed to identify which complement activation pathways are associated with PGD.METHODS We performed a multicenter cohort study at the University of Pennsylvania and Washington University School of Medicine. Bronchoalveolar lavage (BAL) and plasma specimens were obtained from recipients within 24 hours after LTx. PGD was scored based on the consensus definition. Complement activation products and components of each arm of the complement cascade were measured using ELISA.RESULTS In both cohorts, sC4d and sC5b-9 levels were increased in BAL of subjects with PGD compared with those without PGD. Subjects with PGD also had higher C1q, C2, C4, and C4b, compared with subjects without PGD, suggesting classical and lectin pathway involvement. Ba levels were higher in subjects with PGD, suggesting alternative pathway activation. Among lectin pathway–specific components, MBL and FCN-3 had a moderate-to-strong correlation with the terminal complement complex in the BAL but not in the plasma.CONCLUSION Complement activation fragments are detected in the BAL within 24 hours after LTx. Components of all 3 pathways are locally increased in subjects with PGD. Our findings create a precedent for investigating complement-targeted therapeutics to mitigate PGD.FUNDING This research was supported by the NIH, American Lung Association, Children’s Discovery Institute, Robert Wood Johnson Foundation, Cystic Fibrosis Foundation, Barnes-Jewish Hospital Foundation, Danish Heart Foundation, Danish Research Foundation of Independent Research, Svend Andersen Research Foundation, and Novo Nordisk Research Foundation.

Authors

Hrishikesh S. Kulkarni, Kristy Ramphal, Lina Ma, Melanie Brown, Michelle Oyster, Kaitlyn N. Speckhart, Tsuyoshi Takahashi, Derek E. Byers, Mary K. Porteous, Laurel Kalman, Ramsey R. Hachem, Melanie Rushefski, Ja’Nia McPhatter, Marlene Cano, Daniel Kreisel, Masina Scavuzzo, Brigitte Mittler, Edward Cantu III, Katrine Pilely, Peter Garred, Jason D. Christie, John P. Atkinson, Andrew E. Gelman, Joshua M. Diamond

×

Figure 5

Local markers of lectin pathway activation distinguish subjects with PGD.

Options: View larger image (or click on image) Download as PowerPoint
Local markers of lectin pathway activation distinguish subjects with PGD...
Levels of mannose-binding lectin (MBL) in the bronchoalveolar lavage (BAL) highly correlated with markers of complement activation in the BAL (soluble terminal complement complex [TCC]) in the WUSM cohort (A, n = 40). Using a different assay than in Figure 4 (n = 73), BAL MBL levels were higher in subjects who developed PGD compared with the levels in subjects without PGD (C), and this held true in those who developed PGD at or after 24 hours (D). The levels of ficolin-3 (FCN3; B) also highly correlated with BAL TCC (n = 40). r represents Spearman’s rho coefficient. The axes were expressed in a logarithmic scale for purposes of graphical representation. Rank sum tests of comparison (Mann-Whitney U test).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts